Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

Company Overview

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare genetic and endocrine-related disorders of obesity. The company’s lead product, setmelanotide (IMCIVREE), is an FDA-approved melanocortin-4 receptor (MC4R) agonist designed to address the underlying genetic causes of obesity in patients with specific genetic deficiencies, including POMC, PCSK1 and LEPR deficiencies. Beyond its approved indications, Rhythm is actively pursuing additional clinical trials to expand the use of setmelanotide to other rare genetic obesity disorders and exploring its potential in common obesity populations. Founded in 2013 and headquartered in Boston, Massachusetts, Rhythm Pharmaceuticals has established a robust pipeline aimed at transforming the treatment landscape for patients affected by rare obesity disorders. The company’s research and development efforts concentrate on the melanocortin pathway, which plays a central role in energy homeostasis and appetite regulation. Rhythm’s approach combines targeted molecular design with precision medicine, enabling tailored therapies that directly address specific genetic mutations. Its R&D infrastructure includes state-of-the-art laboratories and strategic collaborations with academic institutions and patient advocacy groups worldwide. Rhythm Pharmaceuticals serves a global patient community through a network of specialty pharmacies, healthcare providers and patient support programs. While its primary market is in the United States, the company is pursuing international regulatory approvals and partnerships to extend its reach into Europe and other key markets. Rhythm’s patient-centric initiatives include education, genetic testing support and financial assistance programs aimed at improving access to treatment for individuals with pathogenic genetic variants. Under the leadership of Chief Executive Officer David Meeker, Rhythm has grown its management team and board of directors with experienced professionals in biotechnology, regulatory affairs and commercial strategy. Meeker, previously a key executive at Amicus Therapeutics, brings extensive expertise in rare disease drug development and global commercialization. The company’s leadership team continues to expand as Rhythm advances its clinical programs and prepares for broader market launches.

Key Stats

• Today's Range: $65.61 to $67.44
• 50-Day Range: $56.79 to $68.11
• 52-Week Range: $40.46 to $69.89
• Volume: 628,374 shs
• Average Volume: 557,108 shs
• Market Capitalization: $4.18 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $77.31
• Consensus Rating: Buy

Rhythm Pharmaceuticals Stock Analysis - MarketRank™

Rhythm Pharmaceuticals scored higher than 76% of companies evaluated by MarketBeat, and ranked 712th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Rhythm Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 13 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Rhythm Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.32) to ($2.58) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rhythm Pharmaceuticals is -23.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rhythm Pharmaceuticals is -23.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rhythm Pharmaceuticals has a P/B Ratio of 187.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.97% of the float of Rhythm Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Rhythm Pharmaceuticals has recently decreased by 0.42%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rhythm Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rhythm Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.80

Percentage of Shares Shorted

7.97% of the float of Rhythm Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 6.7.

Change versus previous month

Short interest in Rhythm Pharmaceuticals has recently decreased by 0.42%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.3 / 5
• News Sentiment: 0.28

News Sentiment

Rhythm Pharmaceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Rhythm Pharmaceuticals this week, compared to 8 articles on an average week.

Search Interest

Only 2 people have searched for RYTM on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,930,651.00 in company stock.

Percentage Held by Insiders

Only 6.10% of the stock of Rhythm Pharmaceuticals is held by insiders.

RYTM Stock Analysis - Frequently Asked Questions

How have RYTM shares performed this year?

Rhythm Pharmaceuticals' stock was trading at $55.98 at the beginning of the year. Since then, RYTM shares have increased by 17.5% and is now trading at $65.7750.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings results on Wednesday, May, 7th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by $0.12. The company's quarterly revenue was up 25.9% on a year-over-year basis.
Read the conference call transcript.

When did Rhythm Pharmaceuticals IPO?

Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 5/07/2025
• Today: 7/04/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RYTM
• CIK: 1649904
• Web: www.rhythmtx.com
• Phone: (857) 264-4280
• Fax: 857-264-4299
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $77.31
• High Stock Price Target: $94.00
• Low Stock Price Target: $63.00
• Potential Upside/Downside: +17.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$260.60 million
• Net Margins: -123.26%
• Pretax Margin: -123.19%
• Return on Equity: -739.62%
• Return on Assets: -44.27%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.30
• Quick Ratio: 3.13

Sales & Book Value

• Annual Sales: $130.13 million
• Price / Sales: 32.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.35 per share
• Price / Book: 187.93

Miscellaneous

• Outstanding Shares: 63,620,000
• Free Float: 59,740,000
• Market Cap: $4.18 billion
• Optionable: Optionable
• Beta: 2.26